ArticleMicrobiology spectrum2022
Monitoring SARS-CoV-2 Infection Using a Double Reporter-Expressing Virus.
Article in Microbiology spectrum, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 18 citations in OpenAlex.
- Chimeric SARS-CoV-2 vaccine vectors stably incorporating the functional glycoprotein of VSV.iScience · 2026Article
- A bireporter recombinant SARS-CoV-2 Omicron BA.5 forMicrobiology spectrum · 2026Article
- Recovery of proofreading-impaired SARS-CoV-2 reveals a mutator phenotype and an ExoN activity threshold for viability.Journal of virology · 2026Article
- Development and characterization of mouse-adapted recombinant SARS-CoV-2 expressing reporter genes.Microbiology spectrum · 2026Article
- Differential effects of SARS-CoV-2-targeted infection of ATII, club cells, and macrophages on lung immunopathology and antiviral responses.Mucosal immunology · 2026Article
- Recovery of proofreading-impaired SARS-CoV-2 reveals a mutator phenotype and an ExoN activity threshold for viability.bioRxiv : the preprint server for biology · 2026Article
- A bireporter recombinant SARS-CoV-2 Omicron BA.5 forbioRxiv : the preprint server for biology · 2026Article
- Development of SARS-CoV-2 as a viral vector: A novel intranasal bivalent vaccine for SARS-CoV-2 and RSV.Science advances · 2025Article
- A novel high-throughput screen identifies phenazine-1-carboxylic acid as an inhibitor of African swine fever virus replication in primary porcine alveolar macrophages.Veterinary research · 2025Article
- Advances in the development of infectious clones of human coronaviruses and related applications.Biosafety and health · 2025Review
- Novel replication-competent reporter-expressing Rift Valley fever viruses for molecular studies.Journal of virology · 2025Article
- Kaurenoic acid is a potent inhibitor of SARS-CoV-2 RNA synthesis, virion assembly, and releaseFrontiers in microbiology · 2025Article
- Development and validation of Mayaro virus with luciferase reporter genes as a tool for antiviral assays.Heliyon · 2024Article
- Engineering recombinant replication-competent bluetongue viruses expressing reporter genes forMicrobiology spectrum · 2024Article
- Harnessing preexisting influenza virus-specific immunity increases antibody responses against SARS-CoV-2.Journal of virology · 2024Article
- Development and characterization of a recombinant Senecavirus A expressing enhanced green fluorescent protein.Frontiers in microbiology · 2024Article
- Screening for anti-influenza virus compounds from traditional Mongolian medicine by GFP-based reporter virus.Frontiers in cellular and infection microbiology · 2024Article
- Reverse genetics systems for SARS-CoV-2: Development and applications.Virologica Sinica · 2023Review
- Fluorescent and Bioluminescent Reporter Mouse-Adapted Ebola Viruses Maintain Pathogenicity and Can Be Visualized in Vivo.The Journal of infectious diseases · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the highly contagious agent responsible for the coronavirus disease 2019 (COVID-19) pandemic. An essential requirement for understanding SARS-CoV-2 biology and the impact of antiviral therapeutics is a robust method to detect the presence of the virus in infected cells or animal models. Despite the development and successful generation of recombinant (r)SARS-CoV-2-expressing fluorescent or luciferase reporter genes, knowledge acquired from their use in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.